Magnesium bis(DL-pyroglutamate) | 85994-32-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Magnesium bis(DL-pyroglutamate)
• 英文别名: magnesium;5-oxopyrrolidine-2-carboxylate
• CAS: 85994-32-7
• 化学式: C10H12MgN2O6
• 分子量: 280.52
• InChiKey: JQAACYUZYRBHGG-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -4.35
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  139
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] PYRAZOLES AS MODULATORS OF HEMOGLOBIN<br/>[FR] PYRAZOLES UTILISÉS UTILISÉS COMME MODULATEURS DE L'HÉMOGLOBINE
  申请人：PFIZER

  公开号：WO2020109994A1

  公开（公告）日：2020-06-04

  The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).

  这项发明涉及吡唑衍生物，其在医学上的应用，含有它们的组合物，其制备方法以及用于这些方法的中间体。更具体地，该发明涉及式(I)的HbS调节剂或其互变异构体，或者该调节剂或其互变异构体的药学上可接受的盐，其中X、Y、R2和R3如描述中所定义。HbS调节剂在治疗包括镰状细胞病（SCD）在内的广泛疾病中可能是有用的。
• MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS
  申请人：Neurocentria, Inc.

  公开号：US20170106016A1

  公开（公告）日：2017-04-20

  A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.

  提供了一种用于给予受试者的组合物，例如口服给予受试者。这样的组合物可能包括至少一种镁-对离子化合物。本文描述的镁-对离子组合物可能对本文提供的各种应用有用，例如维护、增强和/或改善受试者的健康、营养和/或其他状态，以及认知、学习和/或记忆功能。本文提供的镁-对离子组合物可能对存在镁缺乏、轻度认知障碍、阿尔茨海默病、注意力缺陷多动障碍、肌萎缩侧索硬化、帕金森病、糖尿病、偏头痛、焦虑障碍、情绪障碍和/或高血压的受试者有用。还提供了一种工具包、方法和其他相关技术。
• Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy
  申请人：Singh Chandra U.

  公开号：US20130189354A1

  公开（公告）日：2013-07-25

  The present invention relates to compositions and methods for treating pain wherein the compositions comprise a combination of tramadol or a pharmaceutically acceptable salt thereof, magnesium or a pharmaceutically acceptable salt thereof; and gabapentin or pregabalin. The therapeutic combination can further contain capsaicin or an ester of capsaicin.

  本发明涉及用于治疗疼痛的组合物和方法，其中所述组合物包括曲马多或其药学上可接受的盐、镁或其药学上可接受的盐；以及加巴嘌醇或普瑞巴林。治疗组合物还可以包含辣椒素或辣椒素酯。
• Microcapsules containing salts for food products
  申请人：Lipofoods, S.L.

  公开号：EP2292102A1

  公开（公告）日：2011-03-09

  The present invention is directed to a composition for delivering edible salts into food products via microcapsules comprising a protein-polysaccharide shell matrix and an edible salt-containing active material.

  本发明涉及一种通过微胶囊将食用盐输送到食品中的组合物，微胶囊由蛋白多糖壳基质和含食用盐的活性材料组成。
• HIGH-LOADING, CONTROLLED-RELEASE MAGNESIUM ORAL DOSAGE FORMS AND METHODS FOR MAKING AND USING SAME
  申请人：Pharmalyte Solutions, LLC

  公开号：EP3243507A1

  公开（公告）日：2017-11-15

  Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels.

  所公开的是用于口服镁盐的高负载、控释剂型。例如，口服剂型可包含约 80% 至约 95% 的乳酸镁和一种或多种成分。另一个例子是，口服剂型可以包含至少约 50%的镁盐，并表现出控释溶解曲线。还公开了制作控释剂型的方法，用于向哺乳动物口服治疗有效量的镁盐。还公开了治疗以镁缺乏为特征的疾病的方法和预防或缓解低镁水平的方法。